Eli Lilly and Company $LLY Stock Holdings Increased by Sustainable Insight Capital Management LLC

Key Points

• Sustainable Insight Capital Management increased its Eli Lilly stake by 18.3% in the first quarter, bringing its holdings to 16,781 shares worth about $15.4 million. LLY now represents roughly 5.2% of the fund’s portfolio.
• Institutional ownership of Eli Lilly remains very high, with hedge funds and other investors holding about 82.53% of the stock. Several large funds, including Norges Bank and Price T Rowe Associates, also reported major positions.
• Analysts remain broadly bullish on Eli Lilly, with multiple firms raising price targets and the consensus rating at Moderate Buy. The stock recently traded near $1,196, and the company also posted strong quarterly results with earnings and revenue both beating expectations.

Sustainable Insight Capital Management LLC lifted its stake in shares of Eli Lilly and Company (NYSE:LLY - Free Report) by 18.3% during the first quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The fund owned 16,781 shares of the company's stock after acquiring an additional 2,600 shares during the period. Eli Lilly and Company accounts for approximately 5.2% of Sustainable Insight Capital Management LLC's portfolio, making the stock its 5th biggest holding. Sustainable Insight Capital Management LLC's holdings in Eli Lilly and Company were worth $15,435,000 at the end of the most recent reporting period.

A number of other hedge funds and other institutional investors have also recently added to or reduced their stakes in LLY. Norges Bank acquired a new stake in shares of Eli Lilly and Company during the 4th quarter worth about $12,976,634,000. J. Stern & Co. LLP raised its position in shares of Eli Lilly and Company by 46,191.3% in the fourth quarter. J. Stern & Co. LLP now owns 4,047,245 shares of the company's stock valued at $4,047,245,000 after buying an additional 4,038,502 shares during the last quarter. Cardano Risk Management B.V. lifted its stake in shares of Eli Lilly and Company by 876.1% during the fourth quarter. Cardano Risk Management B.V. now owns 2,375,050 shares of the company's stock valued at $2,552,419,000 after buying an additional 2,131,734 shares during the period. Fifth Third Bancorp boosted its position in Eli Lilly and Company by 321.3% during the first quarter. Fifth Third Bancorp now owns 1,963,490 shares of the company's stock worth $1,805,959,000 after acquiring an additional 1,497,423 shares during the last quarter. Finally, Price T Rowe Associates Inc. MD boosted its position in Eli Lilly and Company by 10.6% during the fourth quarter. Price T Rowe Associates Inc. MD now owns 14,910,505 shares of the company's stock worth $16,024,022,000 after acquiring an additional 1,432,069 shares during the last quarter. Hedge funds and other institutional investors own 82.53% of the company's stock.

Analysts Set New Price Targets

Several research analysts have weighed in on the company. Guggenheim boosted their price target on Eli Lilly and Company from $1,235.00 to $1,273.00 and gave the company a "buy" rating in a report on Monday, July 13th. Sanford C. Bernstein raised their price objective on Eli Lilly and Company from $1,300.00 to $1,385.00 and gave the stock an "outperform" rating in a report on Tuesday, July 14th. Royal Bank Of Canada lifted their price objective on Eli Lilly and Company from $1,250.00 to $1,500.00 and gave the company an "outperform" rating in a research report on Wednesday, July 8th. Truist Financial upped their target price on Eli Lilly and Company from $1,281.00 to $1,370.00 and gave the company a "buy" rating in a research note on Wednesday, July 8th. Finally, Morgan Stanley increased their target price on Eli Lilly and Company from $1,344.00 to $1,347.00 and gave the stock an "overweight" rating in a research report on Wednesday, July 8th. Two equities research analysts have rated the stock with a Strong Buy rating, twenty-four have issued a Buy rating, four have assigned a Hold rating and one has issued a Sell rating to the company. According to MarketBeat, the stock currently has an average rating of "Moderate Buy" and a consensus target price of $1,283.64.

Eli Lilly and Company Stock Performance

NYSE:LLY opened at $1,196.18 on Friday. The company has a quick ratio of 1.10, a current ratio of 1.50 and a debt-to-equity ratio of 1.26. The company has a market cap of $1.13 trillion, a P/E ratio of 42.49, a P/E/G ratio of 1.50 and a beta of 0.51. Eli Lilly and Company has a fifty-two week low of $623.78 and a fifty-two week high of $1,249.45. The firm's 50 day moving average is $1,136.56 and its two-hundred day moving average is $1,040.15.

Eli Lilly and Company (NYSE:LLY - Get Free Report) last announced its quarterly earnings results on Thursday, April 30th. The company reported $8.55 earnings per share for the quarter, beating analysts' consensus estimates of $6.97 by $1.58. Eli Lilly and Company had a net margin of 34.98% and a return on equity of 105.77%. The company had revenue of $19.80 billion for the quarter, compared to analyst estimates of $17.82 billion. During the same quarter last year, the business earned $3.34 EPS. Eli Lilly and Company's revenue for the quarter was up 55.5% on a year-over-year basis. Eli Lilly and Company has set its FY 2026 guidance at 35.500-37.000 EPS. Analysts expect that Eli Lilly and Company will post 34.21 EPS for the current year.

Eli Lilly and Company Dividend Announcement

The company also recently announced a quarterly dividend, which will be paid on Thursday, September 10th. Investors of record on Friday, August 14th will be issued a $1.73 dividend. The ex-dividend date is Friday, August 14th. This represents a $6.92 dividend on an annualized basis and a yield of 0.6%. Eli Lilly and Company's dividend payout ratio (DPR) is presently 24.58%.

Key Stories Impacting Eli Lilly and Company

Here are the key news stories impacting Eli Lilly and Company this week:

• Positive Sentiment: Eli Lilly reported strong late-stage results for retatrutide, its next-generation obesity drug, in two Phase 3 trials. The drug met its primary endpoint and produced substantial weight loss and A1C improvement, reinforcing expectations for a major future growth franchise. Article Title
• Positive Sentiment: The company said it now plans to file for FDA approval of retatrutide in Q1 2027, keeping the drug on a path toward commercialization and supporting the long-term growth outlook for LLY. Article Title
• Positive Sentiment: A Lilly-backed biotech, Scribe Therapeutics, priced an upsized IPO with strong demand, highlighting continued investor appetite for Lilly-associated pipeline assets and partnerships. Article Title
• Neutral Sentiment: Healthcare stocks were broadly higher late Friday, which may be lending general support to Eli Lilly’s shares. Article Title
• Negative Sentiment: Novo Nordisk is seeking a preliminary injunction to block Lilly’s weight-loss and diabetes ads, accusing the company of using outdated data and misleading comparisons versus Wegovy and Ozempic. That raises legal and regulatory risk for Eli Lilly, even if the impact is likely more headline-driven than fundamental for now. Article Title

Eli Lilly and Company Company Profile

Eli Lilly and Company NYSE: LLY is a global pharmaceutical company founded in 1876 and headquartered in Indianapolis, Indiana. The company researches, develops, manufactures and commercializes a broad range of medicines and therapies for patients worldwide. Eli Lilly maintains operations and commercial presence across North America, Europe, Asia and other regions, serving both developed and emerging markets. The company has been led in recent years by President and Chief Executive Officer David A.

Want to see what other hedge funds are holding LLY? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Eli Lilly and Company (NYSE:LLY - Free Report).

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.